tiprankstipranks
Advertisement
Advertisement
Shrader Reiterates Buy on Invivyd, Maintains $10 Price Target on Strong VYD2311 Prospects and High-Risk Population Opportunity
PremiumRatingsShrader Reiterates Buy on Invivyd, Maintains $10 Price Target on Strong VYD2311 Prospects and High-Risk Population Opportunity
2M ago
Invivyd completes enrollment in DECLARATION trial
Premium
The Fly
Invivyd completes enrollment in DECLARATION trial
2M ago
Invivyd: Buy Rating Reiterated as Clinical and Regulatory Progress Supports Unchanged $10 Price Target
Premium
Ratings
Invivyd: Buy Rating Reiterated as Clinical and Regulatory Progress Supports Unchanged $10 Price Target
3M ago
Invivyd Posts Strong Q1 Results, Advances VYD2311 Programs
PremiumCompany AnnouncementsInvivyd Posts Strong Q1 Results, Advances VYD2311 Programs
3M ago
IVVD Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
IVVD Earnings this Week: How Will it Perform?
3M ago
Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit
Premium
The Fly
Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit
4M ago
Invivyd Advances COVID-19 Program and Launches Measles Antibody
PremiumCompany AnnouncementsInvivyd Advances COVID-19 Program and Launches Measles Antibody
4M ago
Invivyd Earnings Call Highlights Pivotal Trial Momentum
Premium
Company Announcements
Invivyd Earnings Call Highlights Pivotal Trial Momentum
5M ago
Invivyd: Accelerating PEMGARDA Uptake and Strong Cash Runway Position VYD2311 as a De‑Risked Growth Catalyst
Premium
Ratings
Invivyd: Accelerating PEMGARDA Uptake and Strong Cash Runway Position VYD2311 as a De‑Risked Growth Catalyst
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100